PPT-Dolutegravir vs. Raltegravir

SPRING2 Study Dolutegravir versus Raltegravir SPRING2 Design Source Raffi F et al Lancet 201338173543 Dolutegravir 50 mg QD Fixeddose NRTI backbone n 411 Raltegravir. t. he . p. revention . o. f . mother. -to-child . t. ransmission . o. f HIV. MJ Trahan, V Lamarre, ME . Metras. , N Lapointe, F Kakkar. Centre . Hospitalier. . Universitaire. Sainte Justine, . Université. David Spach, MD. Clinical Director, Northwest AETC. Professor of Medicine, Division of Infectious Diseases. University of Washington. Last Updated: October 21, 2013. 2013 . Asilomar. Update. New Occupational . New Treatments for HIV. C. Ryan Tomlin, . Pharm.D. ., BCPS, AAHIVP. Mercy Health Saint Mary’s. Grand Rapids, Michigan. Outline. Newly Released Antiretroviral Medications. Isentress. HD. ® (. raltegravir. 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/RTV) Plus . 2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study. Michael Aboud,. 1. Richard Kaplan,. Generic. HIV . Drugs. on 90-90-90. Esteban Burrone. Medicines Patent Pool. . . Impact in terms of treatment affordability. Impact in making new treatments available faster. Impact in making needed new formulations. New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs) . HIV positive people in low- and middle-income countries including South Africa can be treated for around R900 (US $75 a year) . HIV Drug Resistance (HIVDR) and Antimicrobial Resistance (AMR): Science and Action. IAS 2017 . Paris . 24. th. July 2017. Modelling the cost and cost-effectiveness of responses to . HIV drug resistance. of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. Heather Watts MD Director of HIV Prevention, Program Quality Team Office of the Global AIDS Coordinator Dolutegravir in PEPFAR HIV RNA < 50 copies/mL and CD4 response in the SINGLE trial J Acquir Immune ART . on . IRIS . in the . REALITY . trial. Diana M Gibb . on behalf of. the . REALITY . trial team. Background. The Reality trial, in adults/children . with CD4<100 . cells/µl . initiating ART in sub-Saharan Africa, . –. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RESULTS FROM THE GEMINI STUDIES. 1. Fundación Huesped, Buenos Aires, Argentina; . 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; . Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Last Updated: January 28, 2021. Dolutegravir (. Tivicay. ) . INSTI. Tivicay. . [TIV-eh-kay]. Dolutegravir. Treatment Naïve. : 50 mg once daily with or without food. Judith S. Currier, MD, MSc. Professor of Medicine. University of California Los Angeles. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. R. itonavir to Raltegravir. SWITCHMRK 1 & 2 Trials. Switching from Lopinavir-Ritonavir to Raltegravir. SWITCHMRK 1 & 2 Trials: Study Design. Source: . Eron. JJ, et al. Lancet. 2010;375:396-407..